A 74-year-old male was admitted to Departments of Surgery, Toyonaka Municipal Hospital (Osaka, Japan) for treatment of a pancreatic tumor. Contrast enhanced computed tomography (CT) revealed a mass with small cystic lesions in the pancreatic head and body. Fluorodeoxyglucose-positron emission tomography/CT revealed an abnormal uptake of fluorodeoxyglucose, corresponding to the mass lesions. Upper gastrointestinal endoscopy revealed rough mucosa near the opening of the accessory pancreatic duct, and the mucosa biopsy exhibited adenocarcinoma with no mucin observed. The preoperative diagnosis was pancreatic intraductal tubulopapillary neoplasm (ITPN) with cancerous lesions, and a total pancreatectomy with splenectomy was performed. The resected tissue specimen revealed a solid tumor occupying the entire pancreas with intraductal growth into the main pancreatic duct. Histological examination revealed high-grade dysplastic cells in a tubulopapillary growth pattern without overt mucin production beyond the pancreatic duct. Immunohistochemical staining analysis of the tumor was positive for cytokeratin (CK)7, CK19 and mucin (MUC)1, and negative for MUC2, MUC5AC, MUC6 and caudal type homeobox 2. The tumor was finally diagnosed as pancreatic ITPN with associated invasive cancer. The patient remains well without evident recurrence nine months post-surgery. ITPN is a rare type of epithelial neoplasm of the pancreas, and is characterized by intraductal tubulo-papillary growth, ductal differentiation, limited intracellular mucin production, and cellular dysplasia. The present case report may contribute to improved understanding of how to effectively treat patients with ITPN.
Introduction
Intraductal tubulopapillary neoplasm (ITPN) is a rare type of epithelial neoplasm of the pancreas that is characterized by an intraductal, grossly visible, tubule-forming epithelial neoplasm with cellular dysplasia and ductal differentiation without overt mucin production (1) . To the best of our knowledge, ITPN-like intraductal neoplasm was first recognized by Japanese investigators in the mid 1990s and was studied in 2009 by Yamaguchi et al (2) . Following these reports, ITPN was adopted by the World Health Organization (WHO) classification, which was revised in 2010, as a subclass of intraductal neoplasms of the pancreas, along with intraductal papillary mucinous neoplasm (IPMN). It is estimated that ITPNs account for <1% of all pancreatic exocrine tumor cases and 3% of all pancreatic intraductal neoplasm cases (2) . Due to the rarity of ITPN, information regarding the disease is currently limited, and only a few reports, case series and reviews are available (2, 3) ; thus, the clinicopathological features of ITPN remain to be elucidated. In this context, even a case report of ITPN is essential for further characterizing this disease in order to improve the management and treatment of patients with ITPN. In this report we present a case of pancreatic ITPN with associated invasive cancer that was successfully treated with total pancreatectomy.
Case Report
A 74-year-old male was admitted to the Departments of Surgery, Toyonaka Municipal Hospital (Osaka, Japan) for treatment of a pancreatic tumor. The patient's medical history included alcoholic acute pancreatitis, a renal stone and cerebral infarction. The patient did not exhibit any significant findings on physical examination. The laboratory analysis results were within the normal range, with the exception of the serum glucose level (155 mg/dl; normal range 60-110 mg/dl) and HbA1c-NGSP (7.0%; normal range 4.6-6.2%), which were elevated. The levels of various tumor markers were within the normal range, including carcinoembryonic antigen (2.8 ng/ml; normal range, <5.0 mg/dl), cancer antigen 19-9 (15 U/ml; normal range, <37 U/ml), s-pancreas-1 antigen (8.6 U/ml; normal range, <30 U/ml) and duke pancreatic monoclonal antigen type 2 (46 U/ml; normal range, <150 U/ml), and the serum IgG4 level was also normal (42.8 mg/dl; normal range, 4.8-105 mg/dl). Contrast-enhanced computed tomography (CT) revealed a mass with small cystic lesions in the pancreatic head and body that exhibited a non-uniform contrast effect ( Fig. 1A and B) . The main pancreatic duct at the peripheral side of the mass was dilated to 18 mm (Fig. 1C) . Although the patient was not jaundiced, the lower common bile duct was surrounded by the mass, which was in contact with the portal vein and the superior mesenteric vein. There were no visibly enlarged lymph nodes. Magnetic resonance imaging (MRI), as with CT, revealed small cystic lesions in the mass on T2-weighted images ( Fig. 2A) . The mass in the pancreatic head and body was visualized with high signal intensity on diffusion-weighted images (Fig. 2B ). On MR cholangiopancreatography (MRCP), there were small cystic lesions present in the mass and dilatation of the main pancreatic duct from the pancreatic body to the tail (Fig. 2C) . Upper gastrointestinal endoscopy revealed rough mucosa near the opening of the accessory pancreatic duct and no mucus was observed (Fig. 3A) . Biopsy of the mucosa revealed adenocarcinoma. An 18F-fluorodeoxyglucose (FDG)-positron emission tomography scan revealed abnormal FDG uptake with a maximum standardized uptake value of 4.9 for the mass (Fig. 3B ). Based on the aforementioned findings, the pre-operative diagnosis was pancreatic ITPN with associated cancer lesions. Although IPMN was also considered as another possible differential diagnosis of the mass, this diagnosis was rejected due to the lack of mucous secretion identified. A laparotomy using an upper and middle abdominal median incision was performed under general anesthesia. The whole pancreas was hard, likely due to the patient's previous pancreatitis. As the mass was located in the entire pancreatic head and body, an attempt was made to resect the pancreas on the tail side of the mass, in order to preserve the pancreatic tail. However, it was problematic to separate the pancreatic body and the splenic artery and vein, due to the tissue hardness. Therefore, it was judged to be impossible to preserve the spleen, and a total pancreatectomy with splenectomy was subsequently performed. Lymphadenectomy was performed for dissecting regional lymph nodes. Macroscopic examination of the resected specimen indicated an off-white solid tumor occupying the entire pancreas with intraductal growth of the main pancreatic duct; mucin was not identified (Fig. 4A and B) . Histological examination using hematoxylin and eosin staining revelaed that the tumor exhibited high-grade dysplastic cells in a tubulopapillary growth pattern without the overt production of mucin ( Fig. 4C and D) . The tumor had infiltrated the main pancreatic duct, although the pre-operative CT scan had not revealed any tumors in the main pancreatic duct of the pancreatic tail. The tumor had invaded beyond this to the entire pancreatic parenchyma and serosal invasion and retroperitoneal invasion were observed, whereas vascular invasion was not identified. Among 30 lymph nodes dissected, metastasis was verified to be present in two lymph nodes. The metastases were also identified in the lymph nodes along the common hepatic artery and the Fig. 5 ). The final diagnosis was determined to be pancreatic ITPN with associated invasive cancer. The patient progressed without post-operative complications. Following the surgery, the serum glucose levels were managed with subcutaneous insulin injections. At the time of this report (9 months post-surgery), the patient remains disease-free without evidence of recurrence, and is being followed on an outpatient basis (follow-up is ongoing for 5-years). Alive without recurrence M, male; F, female; H, head of the pancreas; B, body of the pancreas; T, tail of the pancreas; NA, not assigned; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy.
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